Radiation change versus recurrent astrocytoma: Diagnostic utility of the proliferation index?

Eileen H. Bigio, Sarah M. Colvin, Bruce E. Mickey, Charles L. White, Elisabeth J. Rushing

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Differentiation of recurrent glioma from radiation damage can be a challenge to neurologists, neurosurgeons, neuroradiologists, and even neuropathologists. We hypothesized that by evaluating sections of recurrent lesions with proliferation markers we might objectively differentiate between radiation damage gliosis and recurrent astrocytoma. We compared the labeling indices of radiation damage and recurrent neoplasm immunohistochemically, using an antibody to MIB-1, a monoclonal antibody to the Ki-67 proliferation marker. Five of the six recurrent neoplasms were gliomas; four these were astrocytic tumors. In most cases, the MIB-1 LI of radiation damage was < 1% and the LI of recurrent neoplasm was > 3%, with pertinent exceptions. We discuss our findings and their possible interpretation.

Original languageEnglish (US)
Pages (from-to)55-63
Number of pages9
JournalJournal of Neuro-Oncology
Volume41
Issue number1
DOIs
StatePublished - 1999

Fingerprint

Astrocytoma
Radiation
Glioma
Neoplasms
Gliosis
Antibodies

Keywords

  • Astrocytoma
  • Glioma
  • Ki-67
  • MIB-1
  • Proliferation marker
  • Radiation

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Radiation change versus recurrent astrocytoma : Diagnostic utility of the proliferation index? / Bigio, Eileen H.; Colvin, Sarah M.; Mickey, Bruce E.; White, Charles L.; Rushing, Elisabeth J.

In: Journal of Neuro-Oncology, Vol. 41, No. 1, 1999, p. 55-63.

Research output: Contribution to journalArticle

@article{80175cb7b51f4d46b83cd7a21ccfc547,
title = "Radiation change versus recurrent astrocytoma: Diagnostic utility of the proliferation index?",
abstract = "Differentiation of recurrent glioma from radiation damage can be a challenge to neurologists, neurosurgeons, neuroradiologists, and even neuropathologists. We hypothesized that by evaluating sections of recurrent lesions with proliferation markers we might objectively differentiate between radiation damage gliosis and recurrent astrocytoma. We compared the labeling indices of radiation damage and recurrent neoplasm immunohistochemically, using an antibody to MIB-1, a monoclonal antibody to the Ki-67 proliferation marker. Five of the six recurrent neoplasms were gliomas; four these were astrocytic tumors. In most cases, the MIB-1 LI of radiation damage was < 1{\%} and the LI of recurrent neoplasm was > 3{\%}, with pertinent exceptions. We discuss our findings and their possible interpretation.",
keywords = "Astrocytoma, Glioma, Ki-67, MIB-1, Proliferation marker, Radiation",
author = "Bigio, {Eileen H.} and Colvin, {Sarah M.} and Mickey, {Bruce E.} and White, {Charles L.} and Rushing, {Elisabeth J.}",
year = "1999",
doi = "10.1023/A:1006112228001",
language = "English (US)",
volume = "41",
pages = "55--63",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Radiation change versus recurrent astrocytoma

T2 - Diagnostic utility of the proliferation index?

AU - Bigio, Eileen H.

AU - Colvin, Sarah M.

AU - Mickey, Bruce E.

AU - White, Charles L.

AU - Rushing, Elisabeth J.

PY - 1999

Y1 - 1999

N2 - Differentiation of recurrent glioma from radiation damage can be a challenge to neurologists, neurosurgeons, neuroradiologists, and even neuropathologists. We hypothesized that by evaluating sections of recurrent lesions with proliferation markers we might objectively differentiate between radiation damage gliosis and recurrent astrocytoma. We compared the labeling indices of radiation damage and recurrent neoplasm immunohistochemically, using an antibody to MIB-1, a monoclonal antibody to the Ki-67 proliferation marker. Five of the six recurrent neoplasms were gliomas; four these were astrocytic tumors. In most cases, the MIB-1 LI of radiation damage was < 1% and the LI of recurrent neoplasm was > 3%, with pertinent exceptions. We discuss our findings and their possible interpretation.

AB - Differentiation of recurrent glioma from radiation damage can be a challenge to neurologists, neurosurgeons, neuroradiologists, and even neuropathologists. We hypothesized that by evaluating sections of recurrent lesions with proliferation markers we might objectively differentiate between radiation damage gliosis and recurrent astrocytoma. We compared the labeling indices of radiation damage and recurrent neoplasm immunohistochemically, using an antibody to MIB-1, a monoclonal antibody to the Ki-67 proliferation marker. Five of the six recurrent neoplasms were gliomas; four these were astrocytic tumors. In most cases, the MIB-1 LI of radiation damage was < 1% and the LI of recurrent neoplasm was > 3%, with pertinent exceptions. We discuss our findings and their possible interpretation.

KW - Astrocytoma

KW - Glioma

KW - Ki-67

KW - MIB-1

KW - Proliferation marker

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=0032906254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032906254&partnerID=8YFLogxK

U2 - 10.1023/A:1006112228001

DO - 10.1023/A:1006112228001

M3 - Article

C2 - 10222423

AN - SCOPUS:0032906254

VL - 41

SP - 55

EP - 63

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -